Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for …
Industry Peers
Medical Instruments & Supplies| Headline | Source | Time |
|---|---|---|
This week | ||
Older | ||
LLa Libre.be | ||
Nyxoah SA (NYXH) (Q2 2026) Earnings Call Highlights: US Revenue Surges 22% Sequentially, $110M ... Nyxoah SA (NYXH) reports strong US commercial momentum with active accounts doubling to 180, while securing capital to accelerate its launch ramp. | ||
 Nyxoah Q2 Earnings Call Highlights Nyxoah (NASDAQ:NYXH) reported second-quarter worldwide net revenue of €7.7 million, up 21% sequentially from the first quarter, as its U.S. commercial launch continued to expand. U.S. net revenue reached €5.2 million, a 22% increase from the prior quarter, while international revenue rose 19% sequen | ||
LLe Soleil | ||
TTestachats | ||
Nyxoah S.A. Q1 2026 Earnings Call Summary Moby summary of Nyxoah S.A.'s Q1 2026 earnings call | ||
Nyxoah SA (NYXH) Q1 2026 Earnings Call Highlights: Strong U.S. ... Nyxoah SA (NYXH) reports a 25% sequential U.S. revenue increase, while addressing production yield issues impacting gross margins. | ||
Nyxoah Q1 Earnings Call Highlights Nyxoah (NASDAQ:NYXH) reported 13% sequential worldwide net revenue growth in the first quarter of 2026, driven primarily by continued adoption of its Genio system in the United States, where the company is in its second full quarter of commercialization. Chief Executive Officer Olivier Taelman said | ||
 Nyxoah SA (NYXH) Reports Q1 Loss, Tops Revenue Estimates Nyxoah (NYXH) delivered earnings and revenue surprises of +19.88% and +4.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
AAKTus – CCI | ||